Thelansis’s "Myeloproliferative Neoplasms (MPNs) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Myeloproliferative Neoplasms treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Myeloproliferative neoplasms (MPNs) are a group of rare, chronic hematologic malignancies characterized by the clonal expansion of hematopoietic stem cells in the bone marrow, resulting in overproduction of one or more mature blood cell lines, including red blood cells, white blood cells, and platelets. The three “classic” BCR‑ABL1–negative MPNs are polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). These disorders share common driver mutations in JAK2, CALR, or MPL, which lead to constitutive activation of the JAK‑STAT signaling pathway. Clinically, MPNs are associated with an increased risk of thrombotic and hemorrhagic complications, as well as splenomegaly and constitutional symptoms. Over time, they may progress to advanced disease or transform into acute myeloid leukemia (AML). Management is risk‑stratified and focuses on preventing vascular events, controlling blood counts, and alleviating symptoms through phlebotomy, low‑dose aspirin, cytoreductive therapies, JAK inhibitors, and, in selected cases, allogeneic stem cell transplantation.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Myeloproliferative Neoplasms (MPNs) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035 report
Our team will get in touch with you shortly about the Myeloproliferative Neoplasms (MPNs) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035 report.